Royce & Associates LP Has $38.76 Million Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Royce & Associates LP trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 14.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,598,360 shares of the biopharmaceutical company's stock after selling 265,991 shares during the period. Royce & Associates LP owned approximately 1.31% of Catalyst Pharmaceuticals worth $38,760,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Catalyst Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after purchasing an additional 390,116 shares in the last quarter. Renaissance Technologies LLC grew its stake in Catalyst Pharmaceuticals by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company's stock valued at $56,477,000 after purchasing an additional 180,100 shares in the last quarter. Castlekeep Investment Advisors LLC purchased a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $37,494,000. Bank of America Corp DE grew its stake in Catalyst Pharmaceuticals by 139.5% in the fourth quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock valued at $32,741,000 after purchasing an additional 913,843 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Catalyst Pharmaceuticals by 8.7% in the fourth quarter. Northern Trust Corp now owns 1,503,566 shares of the biopharmaceutical company's stock valued at $31,379,000 after purchasing an additional 119,766 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Trading Down 0.8%

NASDAQ:CPRX traded down $0.17 during mid-day trading on Monday, hitting $20.80. 1,304,971 shares of the company's stock traded hands, compared to its average volume of 1,290,795. The firm has a 50 day moving average of $22.96 and a two-hundred day moving average of $22.89. Catalyst Pharmaceuticals, Inc. has a 12 month low of $15.34 and a 12 month high of $26.58. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of 13.25, a price-to-earnings-growth ratio of 0.85 and a beta of 0.66.

Analyst Ratings Changes

Separately, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $32.83.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the sale, the insider owned 41,081 shares in the company, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gary Ingenito sold 44,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the sale, the insider owned 68,873 shares of the company's stock, valued at approximately $1,627,468.99. The trade was a 38.98% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.